{"id":"pegylated-interferon-a-2a","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"60-70","effect":"Headache"},{"rate":"50-60","effect":"Myalgia"},{"rate":"20-30","effect":"Depression and mood disorders"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Neutropenia"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"5-10","effect":"Thyroid dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon alpha-2a is a cytokine that binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes and enhance natural killer cell and macrophage activity. Pegylation extends the drug's half-life by reducing renal clearance and proteolytic degradation. This sustained immune activation is particularly effective against hepatitis C and B viruses, and has antiproliferative effects in certain malignancies.","oneSentence":"Pegylated interferon alpha-2a activates innate immune responses by binding to interferon alpha receptors, enhancing antiviral and antiproliferative activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:11.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"},{"name":"Chronic hepatitis B virus infection"},{"name":"Certain hematologic malignancies (e.g., chronic myeloid leukemia, follicular lymphoma)"}]},"trialDetails":[{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT00877760","phase":"PHASE4","title":"Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2009-08","conditions":"Chronic Hepatitis B","enrollment":184},{"nctId":"NCT01391117","phase":"PHASE1","title":"TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin","status":"TERMINATED","sponsor":"Tibotec BVBA","startDate":"2011-06","conditions":"Hepatitis C Virus","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys"],"phase":"marketed","status":"active","brandName":"pegylated interferon a-2a","genericName":"pegylated interferon a-2a","companyName":"Foundation for Liver Research","companyId":"foundation-for-liver-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha-2a activates innate immune responses by binding to interferon alpha receptors, enhancing antiviral and antiproliferative activity. Used for Chronic hepatitis C virus infection, Chronic hepatitis B virus infection, Certain hematologic malignancies (e.g., chronic myeloid leukemia, follicular lymphoma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}